Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth large-group generic formulary Coverag…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    Large Group Generic Drug List (Formulary) — 2026

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists covered drugs, tiers, and utilization management (e.g., prior authorization, quantity limits, step therapy) for EmblemHealth large-group plans and informs members and providers which drugs are included and any restrictions.

    Policy Summary
    PayerEmblemHealth
    PolicyLarge Group Generic Drug List (Formulary) — 2026
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization when 'PA' is indicated before submitting a claim.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-04-01Formulary effective date
    LGENDrug List ID
    MultipleTier info
    PA, QL, ST, SPUtilization flags
    SeveralExamples with PA

    Coverage Criteria and Conditions

    General coverage condition

    Covered when the following plan rules are met:

    Formulary coverage conditions: Drug is listed on the member's applicable drug list and any applicable utilization management requirements (e.g., PA, QL, ST) or site-of-care rules are satisfied.

    Members should verify specific plan coverage, limits, and cost sharing via their Certificate of Coverage or pharmacy customer service (see member ID card).

    ACA-covered contraceptives

    Covered when ALL of the following are met:

    ACA-covered contraceptives: Contraceptive products identified with Requirements/Limits = ACA (including oral contraceptives, vaginal rings, implants, IUDs, and injectables such as ANNOVERA, NuvaRing, NEXPLANON, MIRENA, PARAGARD, DEPO-PROVERA and similar items) are covered under ACA provisions.

    Some items may also carry LA (limited availability) or other administrative flags; check item line for exact flags and site-of-care notes.

    Policy Summary
    PayerEmblemHealth
    PolicyLarge Group Generic Drug List (Formulary) — 2026
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization when 'PA' is indicated before submitting a claim.
    SourceLink
    On This Page
    Coverage Criteria and ConditionsFormulary Listings and Code TablesPrior Authorization, Step Therapy, and DocumentationStep Therapy RequirementsQuantity Limits (Examples by Product)Site-of-Care and Specialty HandlingBackground and ScopeDefinitions and Abbreviations

    Antidiabetic agents with PA/QL

    Covered when ALL of the following are met:

    PA and/or QL required agents: Select antidiabetic agents (GLP‑1/GIP agents and certain combination oral agents) are covered but require prior authorization (PA) and/or are subject to quantity limits (QL) as listed (examples: MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY; some empagliflozin/metformin combinations and others carry QL entries).

    Clinical criteria for PA (medical necessity documentation, step requirements) are not included in this excerpt; providers should submit PA when indicated.

    Glucose, glucagon, and insulin coverage

    Covered when ALL of the following are met:

    Emergency glucose, glucagon, and insulin products: Emergency glucose products (gels, chewable tabs, oral liquids), glucagon rescue products, and rapid‑acting insulins are listed as covered. Many insulin products and formats have explicit quantity limits noted (examples: FIASP, HUMALOG, LYUMJEV — QLs vary by vial/pen/cartridge).

    Most glucose and glucagon items show Drug Tier = 1 and are covered without additional clinical criteria in this excerpt; insulin and CGM/pump supplies may require PA or QL per item line.

    Product-specific coverage with administrative controls

    Covered when ALL of the following administrative conditions are met:

    Product listing with administrative tags: Items are covered according to their Drug Tier and Requirements/Limits tags; coverage is contingent on meeting the administrative controls shown (e.g., PA, QL, ST, ACA, SP).

    This segment provides administrative tags only; specific clinical medical‑necessity criteria are not present in these chunks. Providers must follow prior authorization and documentation procedures where PA/SP is indicated.

    Itemized coverage with administrative requirements

    Formulary coverage is itemized; coverage for listed devices and kits is subject to the following:

    Itemized coverage with administrative requirements: Insulin pumps, disposable pump pods/kits, and certain device supplies are listed with Drug Tier = 1 but require prior authorization and/or have quantity limits as specified on the item line (examples: ILET INSULIN PUMP, OMNIPOD INTRO KIT, OMNIPOD pods, V‑GO systems).PA and QL per item (see line‑item details)

    Refer to each product line for the exact QL and PA periods (examples shown in the formulary: 1 kit/720 days; 30 pods/30 days; 30 systems/30 days). Providers should submit required PA documentation for device and pump approvals.

    A medicine appearing on the formulary does not guarantee coverage under every EmblemHealth drug benefit. Members must consult their Certificate of Coverage or call the phone number on the back of their ID card to confirm whether a listed drug is covered, applicable copays, and any plan-specific requirements. The formulary notes that some drugs may require additional administrative steps (e.g., PA, QL, ST) before payment will be authorized.

    Within the provided excerpt there are no explicit exclusion statements identifying drugs or classes that are categorically excluded from coverage. The listing shows product entries and Requirements/Limits flags (for example, contraceptives marked ACA), but it does not assert any blanket exclusions in these chunks.

    The document segment reviewed does not contain specific clinical exclusion criteria (for example, disease- or diagnosis-based exclusions). Entries are presented as itemized formulary listings with administrative flags (QL, PA, ACA) rather than clinical exclusion rules.

    No clinical exclusion statements are present in these chunks. The content is an alphabetical product and supplies listing with Requirements/Limits annotations; it does not define clinical criteria that would exclude particular uses or indications in this excerpt.

    This excerpt does not include any explicit determinations that services or drugs are not medically necessary. The text focuses on item-level listing and quantity/authorization flags rather than medical necessity rulings.

    Within this document segment there are no statements labeled as Not Medically Necessary (NMN). The entries describe product listings and administrative controls (e.g., QL, PA) but do not make NMN determinations here.

    No explicit not medically necessary language appears in these chunks. The content is limited to itemized listings, device and supply names, and Requirements/Limits markers without NMN findings.

    Formulary Listings and Code Tables

    Covered drugs and strengths (excerpts)mixedCovered
    amoxicillin (trihydrate) cap 250 mg, 500 mglisted drug and strengths
    amoxicillin & k clavulanate tab 250-125 mg, 500-125 mg, 875-125 mglisted drug and strengths
    cephalexin cap 250 mg, 500 mg, 750 mglisted drug and strengths
    azithromycin tab 250 mg, 500 mglisted drug and strengths
    fidaxomicin tab 200 mg (Dificid)listed drug and strength
    ciprofloxacin hcl tab 250 mg, 500 mg, 750 mg (Cipro)listed drug and strengths
    tobramycin nebu soln 300 mg/5ml (Tobi); Bethkis 300 mg/4mllisted nebule products
    fluconazole tab 50 mg, 100 mg, 150 mg, 200 mg (Diflucan)listed antifungal strengths
    Selected antimicrobial and antifungal agents from listingmixedCovered
    levofloxacin oral soln 25 mg/mllevofloxacin oral soln 25 mg/ml, Drug Tier = 1
    levofloxacin tab 250 mg, 500 mg, 750 mglevofloxacin tab 250 mg, 500 mg, 750 mg, Drug Tier = 1
    moxifloxacin hcl tab 400 mgmoxifloxacin hcl tab 400 mg (base equiv), Drug Tier = 1
    neomycin sulfate tab 500 mgneomycin sulfate tab 500 mg, Drug Tier = 1
    tobramycin nebu soln 300 mg/5ml (Tobi)tobramycin nebu soln 300 mg/5ml (Tobi), Drug Tier = 1, Requirements/Limits = SP
    tobramycin nebu soln 300 mg/4ml (Bethkis)tobramycin nebu soln 300 mg/4ml (Bethkis), Drug Tier = 1, Requirements/Limits = SP
    ethambutol hcl tab 100 mg, 400 mgethambutol hcl tab 100 mg, 400 mg, Drug Tier = 1
    isoniazid syrup 50 mg/5mlisoniazid syrup 50 mg/5ml, Drug Tier = 1
    isoniazid tab 100 mg, 300 mgisoniazid tab 100 mg, 300 mg, Drug Tier = 1
    pyrazinamide tab 500 mgpyrazinamide tab 500 mg, Drug Tier = 1
    1–10 of 19
    1/2
    Selected antiretroviral and antiviral agents with flagsmixedCovered
    voriconazole for susp 40 mg/ml (Vfend)voriconazole for susp 40 mg/ml (Vfend), Drug Tier = 1, Requirements/Limits = PA
    voriconazole tab 50 mg (Vfend)voriconazole tab 50 mg (Vfend), Drug Tier = 1, Requirements/Limits = PA
    voriconazole tab 200 mgvoriconazole tab 200 mg, Drug Tier = 1, Requirements/Limits = PA
    abacavir sulfate soln 20 mg/ml (Ziagen)abacavir sulfate soln 20 mg/ml (Ziagen), Drug Tier = 1, Requirements/Limits = QL (960 mls/30 days)
    abacavir sulfate tab 300 mg (Ziagen)abacavir sulfate tab 300 mg (Ziagen), Drug Tier = 1, Requirements/Limits = QL (60 tablets/30 days)
    abacavir sulfate-lamivudine tab 600-300 mgabacavir sulfate-lamivudine tab 600-300 mg, Drug Tier = 1, Requirements/Limits = QL (30 tablets/30 days)
    APRETUDE - cabotegravir im extended release susp 600 mg/3mlAPRETUDE - cabotegravir im extended release susp 600 mg/3ml, Drug Tier = 1, Requirements/Limits = ACA, LA, SP
    atazanavir sulfate cap (various strengths)atazanavir sulfate cap 150/200/300 mg, Drug Tier = 1, Requirements/Limits = QL (30-60 capsules/30 days)
    darunavir tab 600 mg, 800 mg (Prezista)darunavir tab 600 mg, 800 mg (Prezista), Drug Tier = 1, Requirements/Limits = QL (30-60 tablets/30 days)
    DESCOVY - emtricitabine-tenofovir alafenamide fumarate tab 200-25 mgDESCOVY - emtricitabine-tenofovir alafenamide fumarate tab 200-25 mg, Drug Tier = 1, Requirements/Limits = ACA, QL (30 tablets/30 days)
    Misc anti-infectives and oral vancomycinmixedCovered
    nitazoxanide tab 500 mgnitazoxanide tab 500 mg, Drug Tier = 1, Requirements/Limits = QL (12 tablets/90 days)
    nitrofurantoin formulationsnitrofurantoin macrocrystalline and monohydrate formulations, Drug Tier = 1
    vancomycin hcl cap 125 mg, 250 mg (Vancocin)vancomycin hcl cap 125 mg (base equivalent), 250 mg (base equivalent) (Vancocin), Drug Tier = 1
    vancomycin hcl for oral soln 25 mg/ml, 50 mg/ml (Firvanq)vancomycin hcl for oral soln 25 mg/ml, 50 mg/ml (Firvanq), Drug Tier = 1
    Vaccines with ACA preventive designationmixedCovered
    ABRYSVO - rsv pre-fusion f a&b vac recomb for im soln 120 mcg/0.5mlABRYSVO - RSV pre-fusion vaccine, Drug Tier = 1, Requirements/Limits = ACA
    ACTHIB - haemophilus b polysaccharide conjugate vaccineACTHIB - haemophilus b conjugate vaccine for injection, Drug Tier = 1, Requirements/Limits = ACA
    CAPVAXIVE - pneumococcal 21-valent conjugate vaccineCAPVAXIVE - pneumococcal 21-valent conjugate vaccine, Drug Tier = 1, Requirements/Limits = ACA
    COMIRNATY 2025-26 - COVID-19 mRNA vaccine (Pfizer)COMIRNATY 2025-26 - COVID-19 mRNA vaccine, Drug Tier = 1, Requirements/Limits = ACA
    GARDASIL 9 - human papillomavirus 9-valent vaccineGARDASIL 9 - HPV 9-valent vaccine, Drug Tier = 1, Requirements/Limits = ACA
    PNEUMOVAX 23 - pneumococcal vaccine polyvalentPNEUMOVAX 23 - pneumococcal polyvalent vaccine, Drug Tier = 1, Requirements/Limits = ACA
    PREVNAR 20 - pneumococcal 20-valent conjugate vaccinePREVNAR 20 - pneumococcal 20-valent conjugate vaccine, Drug Tier = 1, Requirements/Limits = ACA
    Formulary product identifiers shown in extractmixed
    MENQUADFImeningococcal (a, c, y, and w-135) tetanus conjugate vaccine
    MENVEOmeningococcal (a, c, y, and w-135) oligo conj vac
    MNEXSPIKE COVID-19 VACCINcovid-19 mrna vaccine-moderna im susp 10 mcg/0.2ml
    MRESVIArsv mrna pre-f vaccine im susp 50 mcg/0.5ml
    NUVAXOVID COVID-19 VACCINcovid-19 subunit vacc-novavax im susp 5 mcg/0.5ml
    PEDVAX HIBhaemophilus b polysaccharide conj vac 7.5 mcg/0.5 ml
    PNEUMOVAX 23pneumococcal vaccine polyvalent soln 25 mcg/0.5ml
    PREVNAR 20pneumococcal 20-valent conjugate vaccine 0.5 ml
    PRIORIXmeasles-mumps-rubella vaccine for subcutaneous susp
    SHINGRIXzoster vaccine recombinant adjuvanted 50 mcg/0.5ml
    1–10 of 14
    1/2
    Selected antineoplastics with utilization flagsmixed
    abiraterone acetate 250 mgZytiga (tablet) — Requirements/Limits = PA, QL
    dasatinib 20 mgSprycel — Requirements/Limits = PA, QL, SP
    everolimus various strengthsAfinitor/Afinitor disperz — Requirements/Limits = PA, QL, SP
    imatinib 100 mg, 400 mgGleevec — Requirements/Limits = PA, QL, SP
    nilotinibTasigna — Requirements/Limits = PA, QL, SP
    pazopanibVotrient — Requirements/Limits = PA, QL, SP
    sorafenibNexavar — Requirements/Limits = PA, QL, SP
    Sample topical/systemic estrogens and formulationsmixedCovered
    estradiol td gel 1.25 mg/1.25gm (0.1%)Divigel — Requirements/Limits = QL (30 packets/30 days) and QL (37.5 grams/30 days) listed
    estradiol td patch (Vivelle-dot)multiple strengths — Requirements/Limits = QL (8 patches/28 days)
    estradiol td patch weekly (Climara)multiple strengths — Requirements/Limits = QL (4 patches/28 days)
    Delestrogen (estradiol valerate IM)various concentrations — Drug Tier = 1
    Contraceptives and IUDs/implantsmixedCovered
    ANNOVERAsegesterone acetate-ethinyl estradiol vaginal ring — Requirements/Limits = ACA
    NEXPLANONetonogestrel subdermal implant 68 mg — Requirements/Limits = ACA, LA
    MIRENAlevonorgestrel IUD 20 mcg/day — Requirements/Limits = ACA, LA
    PARAGARDcopper IUD — Requirements/Limits = ACA, LA
    Antidiabetic agents with PA/QL flagsmixedCovered
    MOUNJAROtirzepatide soln auto-injector — Requirements/Limits = PA, QL (4 pens/180 days or 4 pens/28 days depending on strength)
    OZEMPICsemaglutide soln pen-inj — Requirements/Limits = PA, QL (1 pen/28 days or 3 pens/28 days depending on dose)
    RYBELSUSsemaglutide tablet — Requirements/Limits = PA, QL (30 tablets/180 days or 30 tablets/30 days depending on strength)
    TRULICITYdulaglutide auto-injector — Requirements/Limits = PA, QL (4 pens/28 days or 2 pens/28 days for higher doses)
    JANUMET / JANUMET XR / JANUVIA / JARDIANCEvarious antidiabetics — some have QL or PA flags (examples: JANUMET QL 60/30 days; JANUVIA QL 30/30 days)
    Emergency glucose/glucagon and insulinsmixedCovered
    GLUCAGON (BAQSIMI, GVOKE, GLUCAGON KIT)multiple glucagon products listed — Requirements/Limits = .
    GLUCOSE products (gels, chew tabs, liquids)multiple entries — Drug Tier = 1
    HUMALOG / FIASP / LYUMJEVinsulin lispro and aspart formulations with explicit QL (e.g., 33 pens/30 days, 100 mls/30 days)
    Formulary flags used in this segmentmixed
    FFFormulary Fill (flag shown as FF)
    PAPrior Authorization
    QLQuantity Limit
    SPSpecialty drug flag
    Respiratory agents and inhaled productsmixedCovered
    albuterol sulfate inhal aero 108 mcg/act (90mcg base equiv)Drug Tier = 1; Requirements/Limits = QL (2 inhalers/30 days)
    albuterol sulfate soln nebu 0.083% (2.5 mg/3ml), 0.5% (5 mg/ml), 0.63 mg/3ml, 1.25 mg/3mlDrug Tier = 1
    arformoterol tartrate soln nebu 15 mcg/2ml (Brovana)Drug Tier = 1
    budesonide inhalation susp 0.25 mg/2ml, 0.5 mg/2ml, 1 mg/2ml (Pulmicort)Drug Tier = 1
    budesonide-formoterol fumarate dihyd aerosol 80-4.5 mcg/act, 160-4.5 mcg/act (Symbicort)Drug Tier = 1; Requirements/Limits = QL (3 inhalers/30 days)
    cromolyn sodium soln nebu 20 mg/2mlDrug Tier = 1
    Additional respiratory agents and leukotriene modifiersmixedCovered
    fluticasone-salmeterol aer powder ba 55-14 mcg/act, 113-14 mcg/act, 232-14 mcg/actDrug Tier = 1; Requirements/Limits = QL (1 inhaler/30 days)
    fluticasone-salmeterol aer powder ba 100-50 mcg/act, 250-50 mcg/act, 500-50 mcg/act (Advair diskus)Drug Tier = 1; Requirements/Limits = QL (60 blisters/30 days)
    ipratropium bromide inhal soln 0.02%Drug Tier = 1
    levalbuterol hcl soln nebu conc 1.25 mg/0.5mlDrug Tier = 1
    levalbuterol hcl soln nebu 0.31 mg/3ml, 0.63 mg/3ml, 1.25 mg/3mlDrug Tier = 1
    montelukast sodium chew tab 4 mg, 5 mg (Singulair)Drug Tier = 1
    montelukast sodium tab 10 mg (Singulair)Drug Tier = 1
    Antifibrotic (idiopathic pulmonary fibrosis) agentmixedCovered
    pirfenidone cap 267 mg (Esbriet)Drug Tier = 1; Requirements/Limits = PA, QL (180 capsules/30 days), SP
    pirfenidone tab 267 mg (Esbriet)Drug Tier = 1; Requirements/Limits = PA, QL (180 tablets/30 days), SP
    pirfenidone tab 801 mg (Esbriet)Drug Tier = 1; Requirements/Limits = PA, QL (90 tablets/30 days), SP
    Gastrointestinal agentsmixedCovered
    esomeprazole magnesium for delayed release susp packet 5 mg, 10 mg, 20 mg, 40 mg (Nexium)Drug Tier = 1; Requirements/Limits = QL (60 packets/30 days)
    famotidine for susp 40 mg/5mlDrug Tier = 1; Requirements/Limits = PA, QL (2400 mls/30 days)
    pantoprazole sodium ec tab 20 mg, 40 mg (Protonix)Drug Tier = 1; Requirements/Limits = QL (60 tablets/30 days)
    Antiemetics and renal phosphate bindersmixedCovered
    aprepitant capsule 40 mg, 80 mg, 125 mg (Emend)Drug Tier = 1
    ondansetron hcl oral soln 4 mg/5ml; ondansetron hcl tab 4 mg, 8 mg; ondansetron orally disintegrating tab 4 mg, 8 mgDrug Tier = 1
    lanthanum carbonate chew tab 500 mg, 750 mg, 1000 mg (Fosrenol)Drug Tier = 1; Requirements/Limits = QL (varies by strength: 270/180/120 tablets/30 days respectively)
    sevelamer carbonate packets and tabs (Renvela)Drug Tier = 1; Requirements/Limits = QL (510 packets/30 days for 0.8 gm; QL 150 packets/30 days for 2.4 gm; QL 510 tablets/30 days for 800 mg)
    Genitourinary agents and overactive bladder drugsmixedCovered
    mirabegron tab er 24 hr 25 mg, 50 mg (Myrbetriq)Drug Tier = 1; Requirements/Limits = QL (30 tablets/30 days)
    oxybutynin chloride solution 5 mg/5mlDrug Tier = 1; Requirements/Limits = QL (600 mls/30 days)
    oxybutynin chloride tab er 24hr 5 mgDrug Tier = 1; Requirements/Limits = QL (30 tablets/30 days)
    oxybutynin chloride tab er 24hr 10 mg, 15 mgDrug Tier = 1; Requirements/Limits = QL (60 tablets/30 days)
    solifenacin succinate tab 5 mg, 10 mg (Vesicare)Drug Tier = 1; Requirements/Limits = QL (30 tablets/30 days)
    tamsulosin hcl cap 0.4 mgDrug Tier = 1
    Central nervous system agents and antidepressantsmixedCovered
    alprazolam tab er 24hr 0.5 mg, 1 mg, 2 mg, 3 mg (Xanax XR)Drug Tier = 1
    bupropion hcl tab er 12hr and er 24hr (Wellbutrin SR/XL)Drug Tier = 1; Requirements/Limits = QL (various: 120/90/30/120/180 depending on strength/form)
    citalopram hydrobromide tab 10 mg, 20 mg, 40 mg (Celexa)Drug Tier = 1; Requirements/Limits = QL (120/60/30 tablets/30 days depending on strength)
    Selected device product namesmixed
    DEXCOM G6 RECEIVERcontinuous glucose system receiver
    DEXCOM G6 SENSORcontinuous glucose system sensor
    DEXCOM G6 TRANSMITTERcontinuous glucose system transmitter
    DEXCOM G7 SENSORcontinuous glucose system sensor
    DEXCOM G7 15 DAY SENSORcontinuous glucose system sensor (15 day)
    Selected topical dermatologic drugsmixedCovered
    adapalene-benzoyl peroxide gel 0.1-2.5% (Epiduo)topical acne combination
    tazarotene cream/gel (Tazorac)topical retinoid
    tretinoin cream/gel (Retin-A)topical retinoid
    lidocaine patch/ointment/solutiontopical/local anesthetic products
    Formulary items with PA/QL notes (no billing codes provided in these chunks)mixed
    No codes listed
    Drug list (alphabetical A) — product names present without NDC or CPT codes in these chunksmixed
    No codes listed
    Device/product names (as listed)mixed
    DEXCOM G6 SENSORDexcom G6 sensor product listed
    DEXCOM G7 SENSORDexcom G7 sensor product listed
    Supplies and devicesmixed
    AUTOSOFT 90 INFUSION SETInfusion set product listed
    BD GLUCOSEGlucose monitoring supplies listed
    Example drug formulationsmixed
    cefadroxil cap 500 mgantibiotic formulation listed
    clindamycin phosphate gel 1%topical listing
    Formulary drug entries (sample)mixed
    dimethyl fumarate 240 mgdimethyl fumarate capsule delayed release 240 mg
    dimethyl fumarate starter pack 120/240 mgdimethyl fumarate capsule dr starter pack 120 mg & 240 mg
    diphenoxylate/atropine 2.5/0.025 mgdiphenoxylate w/ atropine tab 2.5-0.025 mg
    dipyridamole 25/50/75 mgdipyridamole tab 25 mg, 50 mg, 75 mg
    Antivirals and cannabinoidsmixed
    dronabinol 2.5/5/10 mgdronabinol cap 2.5 mg; 5 mg, 10 mg
    efavirenz-emtricitabine-tenofovir 600-200-300 mgefavirenz-emtricitabine-tenofovir tab 600-200-300 mg
    emtricitabine 200 mgemtricitabine caps 200 mg
    entecavir 0.5 mg, 1 mgentecavir tab 0.5 mg, 1 mg
    Anticoagulants, antivirals, antifungals, oncologymixed
    enoxaparin variousenoxaparin sodium inj 300 mg/3ml and other strengths
    ergocalciferol 50,000 unitergocalciferol cap 1.25 mg (50000 unit)
    erlotinib 25/100/150 mgerlotinib hcl tab 25 mg, 100 mg, 150 mg
    fluconazole 50/100/150/200 mgfluconazole tab 50 mg, 100 mg, 150 mg, 200 mg
    Neurology and diabetes productsmixed
    glatiramer acetate 20/40 mg/mlglatiramer acetate soln prefilled syringe 20 mg/ml and 40 mg/ml
    gabapentin multiple strengthsgabapentin cap/tab/soln various strengths including once-daily formulations
    insulins (Humalog, Humulin, Insulin Glargine)multiple insulin products and pen/syringe supplies
    Quantity limits (examples)
    Example (liquid antivirals)abacavir sulfate soln 20 mg/ml — QL 960 mls/30 days
    Example (tablets)abacavir sulfate tab 300 mg — QL 60 tablets/30 days
    Example (nitazoxanide)nitazoxanide tab 500 mg — QL 12 tablets/90 days
    Quantity limits examples
    Abiraterone (selected strengths)QL (120 tablets/30 days) or QL (60 tablets/30 days) depending on strength
    Dasatinib (selected strengths)QL (90 tablets/30 days) or QL (30 tablets/30 days) depending on strength
    Example oncology QLEverolimus, nilotinib, and other antineoplastics shown with QL values (e.g., 60–120 tablets/30 days)
    Quantity limit examples
    Oral contraceptive patch (Vivelle-dot)QL (8 patches/28 days)
    Insulin pens (example)FIASP FLEXTOUCH / HUMALOG pen formats — QL examples include 33 pens/30 days or 10 vials/30 days depending on product
    Divice/patch exampleClimara (weekly patch) — QL (4 patches/28 days)
    Quantity Limits (examples)
    Albuterol HFA (inhaler)QL = 2 inhalers/30 days
    Budesonide‑formoterol (Symbicort)QL = 3 inhalers/30 days
    Pirfenidone 267 mgQL = 180 capsules/tablets per 30 days (267 mg strength) — PA and SP also noted
    Examples of quantity limits
    Topical/solution exampleDivigel (estradiol td gel) — QL 37.5 grams/30 days or QL 30 packets/30 days
    Oral/tablet exampleesomeprazole packets (Nexium) — QL 60 packets/30 days
    Smaller tablet exampleMultiple products shown with QL 30 tablets/30 days (common 30/30 pattern)

    Prior Authorization, Step Therapy, and Documentation

    Prior Authorization

    Prior Authorization requirement — Some drugs are subject to Prior Authorization (PA)

    Some drugs listed in the formulary require prior authorization (PA) before the plan will cover them. Providers or members must obtain plan approval in advance; failure to obtain PA may result in claim denial. PA flags appear next to products in the formulary and may be combined with other flags (QL, SP, ACA, LA, ST).

    • Check the member's Certificate of Coverage and plan benefits for specific PA, coverage, and cost-sharing rules.
    • If a drug is marked PA in the formulary, submit a prior authorization request per EmblemHealth procedures before dispensing.
    Prior Authorization

    Prior authorization required for select formulations

    Certain specific formulations (oral solutions, suspensions, capsules, tabs, and strength-specific products) are labeled with PA in the formulary. Examples include nystatin tablets 500, voriconazole (tabs and susp), itraconazole oral solution, and multiple antiretroviral liquid formulations. When a formulation is marked PA, authorization must be obtained for that formulation even if other formulations of the same drug may not require PA.

    • Review the Requirements/Limits column for formulation-level flags (e.g., PA next to a specific strength or formulation).
    • Document medical necessity for the specific formulation when submitting PA (e.g., swallowing difficulty requiring suspension).
    Prior Authorization

    Prior authorization required for PA-designated drugs

    Many oncology, specialty oral agents, and certain injectables are designated PA (often with SP and/or QL). Examples include abiraterone (PA, QL, SP), temozolomide (PA, SP), bexarotene (PA, SP), and various antineoplastics. These PA-designated drugs frequently require clinical documentation and specialty pharmacy handling.

    • When Requirements/Limits shows PA or SP for antineoplastics, include diagnosis, prior therapies, and treatment intent with the PA request.
    • Quantity limits listed (e.g., abiraterone QL 120 tablets/30 days) must be adhered to unless an override is authorized.
    Prior Authorization

    Prior authorization for select antidiabetic injectables and orals

    Select antidiabetic agents — including GLP-1/GIP receptor agonists and related products — are marked PA and often have quantity limits. Examples include MOUNJARO (tirzepatide), OZEMPIC/RYBELSUS (semaglutide), TRULICITY, and liraglutide (Saxenda for weight management). These require PA and may have specific pen/kit limits.

    • MOUNJARO: PA, QL (4 pens/180 days for some strengths; 4 pens/28 days for others).
    • OZEMPIC: PA, QL (1 pen/28 days or 3 pens/28 days depending on strength).
    • RYBELSUS: PA, QL (30 tablets/30–180 days depending on strength).
    • Liraglutide (Saxenda) for weight management: PA, QL (15 mls/30 days).
    Prior Authorization

    Prior authorization and quantity limits

    Some products combine prior authorization (PA) with quantity limits (QL) and/or specialty (SP) designation. When multiple flags appear, PA must be obtained and dispensing must comply with the QL unless an exception is authorized.

    • Examples: abiraterone (PA, QL, SP); pirfenidone (PA, QL, SP); teriparatide (PA, QL, SP).
    • Follow the QL numeric limits on the formulary (e.g., pirfenidone caps 180 capsules/30 days) when submitting claims.
    Prior Authorization

    PA required for pirfenidone — Esbriet formulations

    Pirfenidone (Esbriet) formulations require prior authorization and are subject to quantity limits and specialty designation. Dispense only after PA approval and within stated QL.

    • Pirfenidone cap/tab 267 mg: PA, QL (180 capsules/tablets/30 days) and SP.
    • Higher-strength tablet formulations (e.g., 801 mg) have separate QL (90 tablets/30 days).
    Prior Authorization

    Prior authorization required for select agents and listed products

    Multiple listed products across therapeutic classes are flagged PA (and often SP/QL). Examples include tasimelteon, liraglutide (weight mgmt), phentermine products, cladribine, sodium oxybate, tetrabenazine, and others. Obtain PA and supporting documentation as required.

    • Check Requirements/Limits for PA, SP, LA, ACA flags on individual products before dispensing.
    • High-cost specialty or program-flagged items require supporting clinical documentation (diagnosis, prior therapy, labs) with the PA request.
    Note

    Prior authorization / specialty flags and other program flags

    Products marked with program flags (PA, SP, LA, ACA, FF, ST) trigger utilization management controls. These flags indicate that prior authorization, specialty pharmacy handling, limited availability, Affordable Care Act coverage, frozen formulary implications, or step therapy may apply.

    • ACA = may be covered with no member cost-share when applicable.
    • FF = Frozen Formulary — coverage or utilization may change at plan-year boundaries.
    • LA = Limited Availability — obtainable at select pharmacies only.
    Prior Authorization

    PA and QL required for select pumps and kits

    Specific insulin pumps, starter kits, disposable pod reservoirs, and infusion systems require prior authorization and have quantity limits noted. Requests for these devices should include clinical indication and justification for the specific pump or kit.

    • ILET insulin infusion kit/pump/starter kits: PA, QL (1 kit/720 days or 1 kit/30 days as shown).
    • OMNIPOD Dash and OMNIPOD 5 kits/pods: PA, QL (1 kit/720 days; 30 pods/30 days).
    • V-GO disposable pump kits: PA, QL (30 systems/30 days).
    Note

    Prior Authorization Not Specified in Segment — some listings are index-only

    This segment primarily lists formulary products and flags; not every line specifies prior authorization. Absence of a PA flag in this segment does not guarantee coverage — consult plan details.

    • If Requirements/Limits is blank for a product, confirm coverage and any program rules via the member's plan or prior authorization resources.
    • Some sections are index/listing material and do not include operational PA rules; see plan documents for full requirements.
    Denial Risk

    Potential triggers for denial — obtain PA and follow limits

    Potential triggers for denial include: absence of required prior authorization, exceeding quantity limits, failing step therapy requirements, or not meeting specialty program criteria. Claims submitted without proper PA or documentation may be denied or delayed.

    • Denials commonly occur when PA is required but not obtained prior to dispensing.
    • Claims exceeding QL (e.g., topiramate ER QL 30–60 capsules/30 days; insulin pump kit QL limits) may be denied without documented exception.
    Prior Authorization

    PA-marked products may require prior authorization

    Products marked 'PA' in the formulary may be denied if prior authorization is not obtained. Examples: nystatin tab 500000 unit (PA), voriconazole formulations (PA). Always verify PA status before dispensing.

    • When you see 'PA' next to a product, do not assume coverage at point of sale without approval.
    • Contact EmblemHealth or use the provider portal to initiate PA prior to claim submission.
    Billing Rule

    Quantity limits and specialty/ACA flags — enforce both PA and QL

    Some products combine Quantity Limits (QL) with specialty or ACA flags. Antiretrovirals and other specialty agents often list QL and ACA/SP indicators; these require adherence to both coverage and numerical limits.

    • Examples: abacavir solutions/tabs with QL values; DESCOVY with ACA and QL (30 tablets/30 days); YEZTUGO with ACA, QL (4 tablets/365 days), SP.
    • When ACA or ACA+QL is listed, ensure eligibility rules for ACA apply to the member and that QL is enforced.
    Note

    Utilization management flags — follow indicated controls

    Utilization management flags on the formulary (PA, QL, SP, ST, ACA, FF, LA) indicate controls that affect coverage and dispensing. Providers must review flags and follow the corresponding operational steps (PA submission, QL enforcement, step therapy documentation).

    • ST (Step Therapy): when present, document prior trials per the ST requirements before requesting non-preferred therapies.
    • SP (Specialty): specialty pharmacy handling and additional monitoring may be required; follow SP routing instructions.
    Prior Authorization

    Prior authorization required for select antidiabetics — PA and QL enforcement

    Several high-cost antidiabetic agents are flagged PA (see antidiabetic callout). Quantity limits and PA enforcement are applied to control dispensing frequency and supply amounts.

    • Enforce QL exactly as listed (e.g., MOUNJARO pens QL 4 pens/28 or 180 days depending on strength).
    • PA requirements may include documentation of diagnosis (type 2 diabetes), prior therapies, and weight indication for weight-management products.
    Documentation Required

    Documentation required when PA/QL present — include clinical justification

    When a product lists PA or QL (or both), the provider must include documentation supporting medical necessity, indication, prior treatment history, and dosing. PA submissions lacking required documentation risk denial.

    • Documentation implied by PA/QL: diagnosis, prior therapy failures/intolerances, treatment plan, labs where applicable.
    • For specialty products (SP), include any required enrollment or monitoring documentation with PA.
    Documentation Required

    General documentation note for PA/QL flagged products

    General documentation expectations for flagged products: provide indication, prior therapy trials and dates, relevant lab results, and planned dosing. Pharmacy claims should reflect the drug name, strength, form, and quantity to match QL limits.

    • Ensure claim lines match the formulary-listed strength and form to permit automated QL checks.
    • If requesting an override to a QL or PA, include rationale and supporting clinical records.
    Billing Rule

    Prescription information for QL enforcement — follow QL when dispensing

    When a quantity limit (QL) is listed, dispense according to the numeric limit (e.g., mls/30 days, tablets/30 days). Pharmacy claims must include complete prescription details to allow QL enforcement.

    • Examples: abacavir soln QL 960 mls/30 days; citalopram solution QL 600 mls/30 days; rizatriptan QL 18 tablets/30 days.
    • If a prescription exceeds QL, submit PA with clinical justification prior to dispensing.
    Documentation Required

    Documentation for PA/SP — submit required clinical support

    Prescribers and pharmacists must provide documentation to support PA or specialty (SP) requests per EmblemHealth procedures. This includes clinical notes, prior therapy history, and any program enrollment forms required for SP drugs.

    • For PA/SP requests, include: diagnosis, prior treatments/trials, duration of therapy tried, and relevant diagnostic tests or lab values.
    • Follow payer-specific submission channels (provider portal, fax, or special pharmacy) for SP items.
    Note

    Program-flagged products — operational follow-up required

    Program-flagged products (PA, SP, LA, ACA, FF, ST) require following the payer's operational rules. These flags may trigger specialty pharmacy routing, limited pharmacy availability, or ACA coverage rules.

    • Confirm whether LA (Limited Availability) requires dispensing at specific pharmacies.
    • ACA-marked drugs may have different cost-sharing — verify member eligibility and plan applicability.
    Documentation Required

    Quantity limit and status documentation for devices and supplies

    Quantity limits, status indicators, and program flags must be observed when submitting claims for devices and supplies (e.g., CGM sensors, pump kits). Claims not matching QL or program status may be denied or subject to retrospective review.

    • DEXCOM sensors: QL (2–3 sensors/30 days) and may have ST or other program flags.
    • Pump kits: QL (1 kit/720 days) for some devices; verify device-specific QL before billing.
    Documentation Required

    Required documentation/PA indication — submit complete PA requests

    Submit PA requests with the documentation indicated by the formulary flag. Where PA is required, include all requested clinical information; incomplete submissions delay review and may lead to denial.

    • Use EmblemHealth's PA submission instructions and include all clinical records specified on the PA form.
    • Track PA approvals and authorization numbers; include them on claims per payer guidelines.
    Note

    This segment does not include full PA submission documentation — consult payer resources

    This segment is largely a product listing with flags; it does not contain full operational prior authorization forms, timelines, or appeal procedures. Providers should use EmblemHealth's provider resources for detailed PA submission steps and required forms.

    • For full PA criteria, forms, and turnaround times, consult the EmblemHealth provider portal or call the number on the member ID card.
    • Do not rely solely on the printed formulary listing for operational PA instructions.
    Step Therapy

    Step Therapy requirement — Step/other utilization flags noted

    Step Therapy (ST) may apply to some products in the formulary; flags will indicate when ST is required. The document includes items with ST noted (e.g., CGM sensors) but does not provide step-therapy protocols in this segment.

    • When ST is flagged, document prior trials of preferred agents and durations per plan policy.
    • If no ST details are listed in this segment, obtain ST protocol details from the plan's clinical policy or PA criteria.
    Note

    No explicit step therapy rules are presented in this segment — consult plan documents

    This section does not specify step therapy rules or detailed protocols. Providers must consult plan-specific clinical policies or the Certificate of Coverage for step therapy requirements and exception processes.

    • If a drug is marked ST but no protocol is present here, request ST criteria from EmblemHealth prior to PA submission.
    • Document failed trials of first-line agents when seeking exceptions to ST.

    Step Therapy Requirements

    ProductStep therapy / Notes
    APRETUDE - cabotegravir IM extended release suspension 600 mg/3 mL
    APRETUDE is listed with Requirements/Limits = ACA, LA, SP indicating ACA coverage plus limited access and specialty handling prior to dispensing; some antiretroviral products also show QL (e.g., atazanavir, darunavir, DESCOVY) as noted in the formulary.
    ProductStep therapy / Notes
    MOUNJARO (tirzepatide) pen-injector and OZEMPIC (semaglutide) pen-injector
    These advanced antidiabetic agents are flagged Requirements/Limits = PA and have quantity limits (e.g., MOUNJARO QL 4 pens/180 days or QL 4 pens/28 days for other strengths; OZEMPIC QL 1 pen/28 days or QL 3 pens/28 days) — prior authorization may include step requirements though specific step rules are not provided in this excerpt.
    ProductStep therapy / Notes
    Glycerol phenylbutyrate (Ravicti); JYNARQUE (tolvaptan); APRETUDE; select products flagged LA or SP
    Entries flagged with SP, LA, or 'Y' denote additional utilization controls — specialty routing, limited access, or program requirements before coverage (examples include Ravicti = FF, PA, SP, Y; JYNARQUE = LA, PA, QL, SP; APRETUDE = ACA, LA, SP).
    ProductStep therapy / Notes
    Sildenafil, tadalafil, vardenafil and other PDE5 agents (erectile dysfunction)
    These erectile dysfunction agents are listed with quantity limits (e.g., sildenafil QL 6 tablets/30 days; tadalafil QL 6 or QL 30 tablets/30 days depending on formulation) but no explicit step therapy sequences are described in the provided chunks.
    ProductStep therapy / Notes
    Gabapentin (once-daily formulations, e.g., Gralise 300 mg, 450 mg, 750 mg, 600 mg, 900 mg)
    Certain once-daily gabapentin formulations are marked ST (step therapy) and QL (e.g., Gralise 300/450/750 mg QL 30 tablets/30 days ST; 600 mg QL 90 tablets/30 days ST; 900 mg QL 60 tablets/30 days ST) — approval requires failure of preferred options per plan.
    ProductStep therapy / Notes
    Selected formulations with ST flag (various)
    Some formulations are noted as ST (step therapy) in the formulary and may require trial of alternative formulations or preferred products before approval; examples in the excerpt include notation that certain formulations carry the ST flag though specific product-level examples are limited in these chunks.
    ProductStep therapy / Notes
    Topiramate ER (sprinkle) capsule formulations, selected strengths (e.g., 25 mg, 50 mg, 100 mg, 150 mg, 200 mg)
    Selected topiramate ER (sprinkle) strengths are listed with Requirements/Limits = PA and QL (e.g., 25–150 mg QL 30 capsules/30 days; 200 mg QL 60 capsules/30 days) — prior authorization is required for some ER strengths before coverage.
    ProductStep therapy / Notes
    Vigabatrin (Sabril) and selected specialty agents
    Vigabatrin and some other agents are indicated with SP or LA flags (e.g., JYNARQUE also shows LA, PA, QL, SP) implying enrollment or handling through a specialty program or limited access process prior to coverage.
    ProductStep therapy / Notes
    Dexcom G6 and G7 sensors, transmitters, receivers (continuous glucose monitoring supplies)
    Dexcom G7 and G6 sensors are listed with QL (e.g., QL 3 sensors/30 days or QL 2 sensors/30 days for 15‑day sensors) and are marked ST, indicating step therapy requirements apply prior to approval for sensors/transmitters/receivers.
    ProductStep therapy / Notes
    Various alphabetical product listings in this excerpt
    The listed chunks do not describe step therapy rules for these entries; the segment is an itemized formulary listing without explicit step therapy rules in the provided text.
    StepStep details
    Step 1
    No specific Step 1 clinical details or required agents are provided in the excerpt — step therapy placeholders are noted but not defined in these chunks.

    Quantity Limits (Examples by Product)

    abacavir sulfate soln 20 mg/ml — quantity limit
    Abacavir sulfate soln 20 mg/mlQuantity limit: 960 mls per 30 days
    Source listingReferenced in formulary extract under antiviral/antiretroviral section
    Coverage noteQuantity limits apply per member's applicable drug list and must be observed when dispensing

    Site-of-Care and Specialty Handling

    Note
    Note
    Note

    Background and Scope

    This formulary lists both brand-name and generic drugs and shows the drug tier and any utilization management controls such as PA (Prior Authorization), QL (Quantity Limit), ST (Step Therapy), and specialty flags (e.g., SP, LA). It is intended as an itemized guide for members and prescribers: coverage of a listed drug is conditional on the member’s specific plan, and products flagged with PA, QL, ST or other program markers require the corresponding administrative processes to be satisfied before coverage is authorized. Members should verify plan-specific coverage via their Certificate of Coverage or member services.

    Definitions and Abbreviations